Paranasal sinus neoplasm
diseaseOn this page
Also known as accessory sinus neoplasmaccessory sinus tumoraccessory sinus tumourneoplasm of accessory sinusneoplasm of paranasal sinusneoplasm of the accessory sinusneoplasm of the paranasal sinusparanasal sinus neoplasm (disease)paranasal sinus neoplasmsparanasal sinus tumorparanasal sinus tumourtumor of accessory sinustumor of paranasal sinustumor of the accessory sinustumor of the paranasal sinustumour of accessory sinustumour of paranasal sinustumour of the accessory sinustumour of the paranasal sinus
Summary
Paranasal sinus neoplasm (MONDO:0005289) is a cancer (an umbrella term covering 6 Mondo subtypes) and 5 clinical trials. Top therapeutic interventions include cisplatin, docetaxel anhydrous, and hydroxyurea. A subtype of paranasal sinus disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 6 Mondo subtypes
- Clinical trials: 5
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | paranasal sinus neoplasm |
| Mondo ID | MONDO:0005289 |
| EFO | EFO:0003866 |
| DOID | DOID:1350 |
| NCIT | C7488 |
| SNOMED CT | 126675008 |
| UMLS | C0030470 |
| MedGen | 18296 |
| GARD | 0024171 |
| Anatomy (UBERON) | UBERON:0001825 |
| Is cancer (heuristic) | yes |
Also known as: accessory sinus neoplasm · accessory sinus tumor · accessory sinus tumour · neoplasm of accessory sinus · neoplasm of paranasal sinus · neoplasm of the accessory sinus · neoplasm of the paranasal sinus · paranasal sinus neoplasm · paranasal sinus neoplasm (disease) · paranasal sinus neoplasms · paranasal sinus tumor · paranasal sinus tumour · tumor of accessory sinus · tumor of paranasal sinus · tumor of the accessory sinus · tumor of the paranasal sinus · tumour of accessory sinus · tumour of paranasal sinus · tumour of the accessory sinus · tumour of the paranasal sinus
Data availability: 1 HPO phenotype.
Disease family
This is a subtype of paranasal sinus disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › otorhinolaryngologic disease › nasal disorder › paranasal sinus disorder › paranasal sinus neoplasm
Related subtypes (6): sinusitis, maxillary sinus cholesteatoma, polyp of sphenoidal sinus, polyp of frontal sinus, polyp of maxillary sinus, polyp of ethmoidal sinus
Subtypes (6): frontal sinus neoplasm, ethmoidal sinus neoplasm, sphenoidal sinus neoplasm, paranasal sinus Schneiderian papilloma, maxillary sinus neoplasm, paranasal sinus cancer
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Cisplatin | Phase 3 (in late-stage trials) |
| Fluorouracil | Phase 3 (in late-stage trials) |
| Hydroxyurea | Phase 3 (in late-stage trials) |
Clinical trials & evidence
Clinical trials
Clinical trials: 5.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 2 |
| PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00117572 | PHASE3 | COMPLETED | Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) |
| NCT06940180 | PHASE2 | RECRUITING | Toripalimab With Chemotherapy for Sinus Cancer |
| NCT00462735 | PHASE2 | COMPLETED | Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer |
| NCT00970502 | PHASE1/PHASE2 | COMPLETED | Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer |
| NCT00347256 | Not specified | WITHDRAWN | Chemoradiotherapy Followed by Surgery for Advanced Paranasal Sinus Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CISPLATIN | 4 | 3 |
| DOCETAXEL ANHYDROUS | 4 | 3 |
| HYDROXYUREA | 4 | 2 |
| CHEMBL1510899 | 0 | 1 |
Related Atlas pages
- Drugs: Cisplatin, Docetaxel, Hydroxyurea